Prosecution Insights
Last updated: July 17, 2026

Apnimed Inc. (Delaware)

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
4
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (50%)
1
Easy (25%)
1
Unknown (25%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
§102 only1 (25%)
§112 only1 (25%)
No statute on record1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MCDOWELL, BRIAN E 1 74.2% +30.4%
RAHMANI, NILOOFAR 1 77.5% -3.1%
MAHLUM, JONATHAN DAVIS 1 53.3% +19.0%
SEITZ, ANTHONY JOSEPH 1 67.0% +26.9%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18571847 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION MCDOWELL, BRIAN E
18286399 COMBINATION OF NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA MAHLUM, JONATHAN DAVIS
18283303 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA SEITZ, ANTHONY JOSEPH

Top Art Units

Art UnitApps
1624 1
1691 1
1625 1
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18571847 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION MCDOWELL, BRIAN E 1624 §112 Non-Final OA Pending Dec 19, 2023
18570673 NOREPINEPHRINE REUPTAKE INHIBITORS FOR TREATING SLEEP APNEA RAHMANI, NILOOFAR 1691 §102 Non-Final OA Pending Dec 15, 2023
18286399 COMBINATION OF NOREPINEPHRINE REUPTAKE INHIBITOR AND A CANNABINOID FOR USE IN TREATING SLEEP APNEA MAHLUM, JONATHAN DAVIS 1625 Other Non-Final OA Pending Oct 11, 2023
18283303 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA SEITZ, ANTHONY JOSEPH 1629 §103 Non-Final OA Pending Sep 21, 2023

Managing Apnimed Inc. (Delaware)'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month